Prot#CVAY736B2201: A Two-Part Randomized, Double-Blind, Placebo-Controlled Multicenter Dose Ranging and Confirmatory Study to Assess the Safety and Efficacy of VAY736 in Autoimmune Hepatitis Patients with Incomplete Response to or Intolerance of Standard

Project: Research project

Project Details

StatusActive
Effective start/end date1/14/1912/31/21

Funding

  • Novartis Pharmaceuticals Corporation (CVAY736B2201)